Ernexa Therapeutics Inc. (ERNA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -2.26M | -1.15M | -1.27M | -2.53M | -2.06M | -3.54M | -6.29M | -2.26M | -3.75M | -4.66M | -5.83M | -3.87M |
| Operating CF Margin % | - | - | - | - | - | -354500% | -1290.55% | -4806.38% | -7972.34% | -27417.65% | -11423.53% | - |
| Operating CF Growth % | -9.64% | 67.62% | 79.76% | -12.08% | 44.89% | 23.94% | -7.88% | 41.66% | 38.06% | 14.24% | 4.74% | 3.03% |
| Net Income | -5.51M | -1.5M | -1.24M | -3.14M | -8.2M | -5.76M | -26.6M | -5.53M | -6.65M | -6.15M | -5.59M | -4.51M |
| Depreciation & Amortization | 86K | 69K | 70K | 55K | 69K | 68K | 451K | 578K | 541K | 481K | 517K | 63K |
| Stock-Based Compensation | 0 | 333K | 293K | 368K | 502K | 410K | 405K | 423K | 282K | 165K | 0 | 214K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.45M | 2K | -374K | 690K | 5.34M | 3.16M | 22.74M | 517K | 1.1M | 491K | 206K | 393K |
| Working Capital Changes | 707K | -50K | -21K | -506K | 226K | -1.43M | -3.28M | 1.75M | 980K | 355K | -958K | -34K |
| Change in Receivables | 750K | -692K | 0 | 2K | 281K | -250K | 41K | 123K | 74K | 1.35M | -792K | -337K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 759K | 223K | 0 | -410K | -53K | -575K | -791K | 1.09M | 461K | -4.11M | 1.67M | 1.31M |
| Cash from Investing | -2K | -15K | -22K | 0 | 0 | 0 | -19K | -249K | -97K | -19K | 0 | 0 |
| Capital Expenditures | -2K | -15K | -22K | 0 | 0 | 0 | -19K | -249K | -101K | -19K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | 3.9% | 529.79% | 214.89% | 111.76% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4K | 0 | 0 | 0 |
| Cash from Financing | 9.56M | 0 | 26K | 4.93M | 2.25M | 1.01M | 3.89M | -22K | 1.39M | 7.7M | 8.54M | 312K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 2.25M | 0 | 3.89M | 0 | 1.41M | 7.71M | 8.54M | 0 |
| Equity Issued (Net) | 9.56M | 0 | 0 | 4.93M | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 320K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 8K | 0 | 0 | 0 | -8K | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 26K | 0 | 0 | 1M | 0 | -22K | -20K | 0 | 0 | -8K |
| Net Change in Cash | 7.29M | -1.16M | -1.27M | 2.4M | 189K | -2.54M | 1.68M | -2.53M | -2.46M | 3.02M | 2.71M | -3.56M |
| Free Cash Flow | -2.27M | -1.16M | -1.29M | -2.53M | -2.06M | -3.54M | -6.3M | -2.51M | -3.85M | -4.68M | -5.83M | -3.87M |
| FCF Margin % | - | - | - | - | - | -354500% | -1294.46% | -5336.17% | -8187.23% | -27529.41% | -11423.53% | - |
| FCF Growth % | -9.73% | 67.19% | 79.47% | -0.96% | 46.34% | 24.25% | -8.2% | 35.23% | 36.39% | 14.22% | 5.41% | 7.37% |
| FCF per Share | -2.86 | -3.70 | -3.93 | -12.22 | -0.97 | -1.72 | -29.13 | -11.59 | -17.78 | -21.63 | -26.92 | -18.25 |
| FCF Conversion (FCF/Net Income) | 0.41x | 0.76x | 1.03x | 0.81x | 0.25x | 0.62x | 0.24x | 0.41x | 0.56x | 0.76x | 1.04x | 0.86x |
| Interest Paid | 0 | 0 | 1K | 0 | 0 | 2K | 0 | 6K | 0 | 0 | 0 | 12K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2K | 0 | 0 | 0 | 4K |